Method for predicting and detecting tumor metastasis
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsYoke Peng Loh, Niamh X. Cawley, Saravana Radha Krishna Murthy, Terence K. Lee
Life of this patent
Estimating the term…
Abstract
The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof.
Claims38
A method of determining the prognosis of cancer in a subject, the method comprising
- (a) obtaining a sample from the subject,
- (b) analyzing the sample for an expression level of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN), and
- (c) correlating the expression level of CPE-ΔN in the sample to the prognosis of cancer in the subject.
A method of diagnosing cancer in a subject, the method comprising
- (a) obtaining a sample from the subject,
- (b) analyzing the sample for an expression level of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN), and
- (c) correlating the expression level of CPE-ΔN in the sample to a diagnosis of cancer in the subject.
A method of treating cancer in a subject, comprising administering an effective amount of an inhibitor of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN) to a subject to treat a cancer in the subject.
A composition comprising an inhibitor of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN) and a pharmaceutically acceptable carrier.
An isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 25, SEQ ID NO:
- 26, and SEQ ID NO:
- 27.
A kit for detecting mRNA expression of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN) or polypeptide levels of CPE-ΔN comprising one or more primers or probes that detect CPE-ΔN mRNA or CPE-ΔN polypeptide.
A method of detecting expression of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN) or polypeptide levels of CPE-ΔN in a sample comprising
- (a) obtaining a sample from the subject, and
- (b) contacting the sample with one or more primers or probes that detect CPE-ΔN mRNA or CPE-ΔN polypeptide,
- thereby detecting expression of CPE-ΔN mRNA or CPE-ΔN polypeptide levels.
Dependencies are inferred from the claim text.